ALVION PRODUCTS
Explore our products
Developing and manufacturing noninfringing generic medicines in Europe.
Lenvatinib Capsules
Atorvastatin + Ezetimibe Film Coated Tablets
Rosuvastatin + EzetimibeFilm Coated Tablets
Ticagrelor Film Coated Tablets
Lenvatinib Capsules
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Lenvatinib | Capsules | 4 mg 10 mg | Renal cell carcinoma and Hepatocellular carcinoma | Lenvima® / Kisplyx® | Q2/2026 |
Atorvastatin + Ezetimibe Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Atorvastatin + Ezetimibe | Film Coated Tablets | 10mg+10mg 20mg+10mg 40mg+10mg 80mg+10mg | Cholesterol and triglyceride regulator | Atozet® | Launched |
Rosuvastatin + EzetimibeFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Rosuvastatin + Ezetimibe | Film Coated Tablets | 5mg+10mg 10mg+10mg 20mg+10mg 40mg+10mg | Cholesterol and triglyceride regulator | Crestor®+Ezetrol® | Launched |
Ticagrelor Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Ticagrelor | Film Coated Tablets | 60mg/90mg | Antithrombotic | Brilique® | Completed |
RivaroxabanFilm Coated Tablets
Sitagliptin (Hydrochloride)Film Coated Tablets
Sitagliptin (Hydrochloride) + Metformin IRFilm Coated Tablets
Sitagliptin + Metformin XRFilm Coated Tablets
RivaroxabanFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Rivaroxaban | Film Coated Tablets | 2.5mg 10mg 15mg20mg | Oral anticoagulant | Xarelto® | Completed |
Sitagliptin (Hydrochloride)Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Sitagliptin (Hydrochloride) | Film Coated Tablets | 25mg 50mg 100mg | Oral antidiabetic | Januvia® | Launched |
Sitagliptin (Hydrochloride) + Metformin IRFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Sitagliptin (Hydrochloride) + Metformin IR | Film Coated Tablets | 50mg+850mg 50mg+1000mg | Oral antidiabetic | Janumet® | Launched |
Sitagliptin + Metformin XRFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Sitagliptin + Metformin XR | Film Coated Tablets | 50mg+500mg 50mg+1000mg 100mg+1000mg | Oral antidiabetic | Janumet XR® | Q2/2026 |
Mirabegron PRProlonged released f.c. tablets
Mirabegron + SolifenacinFilm Coated Tablets
ApixabanFilm Coated Tablets
ApixabanOral Solution
Mirabegron PRProlonged released f.c. tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Mirabegron PR | Prolonged released f.c. tablets | 25mg 50mg | Urinary antispasmodic | Betmiga® | Q3/2026 |
Mirabegron + SolifenacinFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Mirabegron + Solifenacin | Film Coated Tablets | 25mg+5mg 50mg+5mg | Urinary antispasmodic | Betmiga®/Vesicare® | Q3/2026 |
ApixabanFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Apixaban | Film Coated Tablets | 2.5mg 5mg | Oral anticoagulant | Eliquis® | Completed |
ApixabanOral Solution
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Apixaban | Oral Solution | 1mg/ml | Oral anticoagulant | Eliquis® | Q2 2026 |
Vortioxetine Film Coated Tablets
Dapagliflozin Film Coated Tablets
Dapagliflozin + Metformin IR Film Coated Tablets
Dapagliflozin + Metformin XRFilm Coated Tablets
Vortioxetine Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Vortioxetine | Film Coated Tablets | 5mg 10mg 15mg 20mg | Antidepressant | Brintellix® | Completed |
Dapagliflozin Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Dapagliflozin | Film Coated Tablets | 5mg 10mg | Oral antidiabetic | Forxiga® | Completed |
Dapagliflozin + Metformin IR Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Dapagliflozin + Metformin IR | Film Coated Tablets | 5mg+850mg 5mg+1000mg | Oral antidiabetic | Xigduo® | Q1 2026 |
Dapagliflozin + Metformin XRFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Dapagliflozin + Metformin XR | Film Coated Tablets | 5mg + 500mg 5mg + 1000mg 10mg + 500mg 10mg + 1000mg | Oral antidiabetic | Xigduo XR® | Q4 2026 |
EmpagliflozinFilm Coated Tablets
Empagliflozin + Metformin Film Coated Tablets
Empagliflozin + LinagliptinFilm Coated Tablets
LisdexamfetamineCapsules
EmpagliflozinFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Empagliflozin | Film Coated Tablets | 10mg 25mg | Oral antidiabetic | Jardiance® | Q2 2026 |
Empagliflozin + Metformin Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Empagliflozin + Metformin | Film Coated Tablets | 5mg+850mg 5mg+1000mg12.5mg+850mg12.5mg+ 1000mg | Oral antidiabetic | Synjardy® | Q3 2026 |
Empagliflozin + LinagliptinFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Empagliflozin + Linagliptin | Film Coated Tablets | 10mg+5mg 25mg+5mg | Oral antidiabetic | Glyxambi® | Q4 2026 |
LisdexamfetamineCapsules
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Lisdexamfetamine | Capsules | 10mg 20mg 30mg 40mg 50mg 60mg 70mg | Attention deficit hyperactivity disorder (ADHD) | Vyvanse® | Q1 2026 |
Bempedoic acidFilm Coated Tablets
Bempedoic acid + EzetimibeFilm Coated Tablets
CariprazineHard Capsules
ApalutamideFilm Coated Tablets
Bempedoic acidFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Bempedoic acid | Film Coated Tablets | 180mg | Refractory hypercholesterolemia | Nexletol® | Q2 2026 |
Bempedoic acid + EzetimibeFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Bempedoic acid + Ezetimibe | Film Coated Tablets | 180mg+10mg | Refractory hypercholesterolemia | Nexlizet® | Q3 2026 |
CariprazineHard Capsules
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Cariprazine | Hard Capsules | 1.5mg3mg4.5mg6mg | Schizophrenia | Vraylar® | Q2 2027 |
ApalutamideFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Apalutamide | Film Coated Tablets | 60mg240mg | Prostate cancer | Erleada® | Q3 2026 |
Sacubitril + ValsartanFilm Coated Tablets
DesmopressinSublingual Tablets
Pitolisant Film Coated Tablets
Brexpiprazol Film Coated Tablets
Sacubitril + ValsartanFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Sacubitril + Valsartan | Film Coated Tablets | 24mg+26mg49mg+51mg97mg+103mg | Chronic heart failure | Entresto® | Q2 2026 |
DesmopressinSublingual Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Desmopressin | Sublingual Tablets | 60mcg120mcg240mcg | Primary Nocturnal Enuresis | Nocdurna® | Completed |
Pitolisant Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Pitolisant | Film Coated Tablets | 4.5mg / 18mg | Excessive Daytime Sleepness (EDS) | Wakix® | Q1/2027 |
Brexpiprazol Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Brexpiprazol | Film Coated Tablets | 1mg 2mg 3mg 4mg | Major Depressive Disorder | Rxulti® | Q2/2027 |
Sitagliptin + (Phosphate)Film Coated Tablets
Sitagliptin (Phosphate) + Metformin IRFilm Coated Tablets
Resmetirom Film Coated Tablets
Sitagliptin + (Phosphate)Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Sitagliptin + (Phosphate) | Film Coated Tablets | 25mg 50mg 100mf | Oral Antidiabetic | Januvia® | Launched |
Sitagliptin (Phosphate) + Metformin IRFilm Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Sitagliptin (Phosphate) + Metformin IR | Film Coated Tablets | 50mg+850mg 50mg+1000mg | Oral Antidiabetic | Januvia® | Launched |
Resmetirom Film Coated Tablets
| Product | Pharmaceutical form | Strengths | Therapeutic category | Reference | Dossier status |
|---|---|---|---|---|---|
| Resmetirom | Film Coated Tablets | 80mg 100mg | Noncirrhotic metabolic dysfunction-associated s teatohepatitis (MASH) with moderate to advanced liver fibrosis | Rezdiffra® | Q3/2028 |
